On track to report interim results from approximately 25 six-month evaluable BCG-Unresponsive patients in ADVANCED-2 trial in Q1 2026Received ...

TARA-002 selected for FDA manufacturing development and readiness pilot program. NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- ...

In December 2025, Palvella requested a Preliminary Breakthrough Therapy Designation Advice meeting with the FDA which is anticipated for the first quarter of 2026. The Company plans to commence a ...

Superintendent Michael Nagler had faced questions over a controversial learning management system developed with his son, an ...

BLR announced that TrainingToday, its workforce training platform, has been awarded in the Best Advance in Learning ...

Lymphatic malformations (LMs) are congenital vascular anomalies characterized by abnormal lymphatic development, leading to ...

This month, I’ll share some of the free software I use to understand how TV signals make it from the transmitter to the ...

Phase 3 SELVA study evaluating QTORIN rapamycin 3.9% anhydrous gel (QTORIN rapamycin) for microcystic lymphatic malformations (microcystic LMs) remains on track, with topline results anticipated in Ma ...

Latin Metals Inc. ("Latin Metals" or the "Company") (TSXV: LMS) (OTCQB: LMSQF) is pleased to provide shareholders with an overview of project ...

Cybersecurity awareness must reach employees and everyday people alike. Through NTT DOCOMO gacco, SAYA delivers ...